PRESS RELEASES

Date Title and Summary View
Jan 5, 2011
Summary ToggleZafgen Announces Positive Topline Phase 1b Data for ZGN-433 in Obesity

Findings Show MetAP2 Inhibition Treatment Drives Significant Weight Loss with Excellent Tolerability and Favorable Metabolic Effects

Summary ToggleZafgen Announces Positive Topline Phase 1b Data for ZGN-433 in Obesity
Jun 26, 2010
Summary ToggleZafgen Presents Data on a New Class of Medicines to Treat Obesity at the American Diabetes Association Annual Meeting

Data Show Treatment with MetAP2 Inhibitor Eliminates Excess Body Fat through Regulation of Fat Metabolism and Food Intake and Normalizes Glucose Tolerance in Preclinical Models

Summary ToggleZafgen Presents Data on a New Class of Medicines to Treat Obesity at the American Diabetes Association Annual Meeting
Oct 26, 2009
Summary ToggleZafgen, Inc. to Present at Upcoming Conferences Summary ToggleZafgen, Inc. to Present at Upcoming Conferences
Jun 29, 2009
Summary ToggleZafgen, Inc. Named One of the “Fierce 15” Leading Biotech Companies of 2009 Summary ToggleZafgen, Inc. Named One of the “Fierce 15” Leading Biotech Companies of 2009
Jun 17, 2009
Summary ToggleZafgen, Inc. Announces Participation at XSITE 2009 Summary ToggleZafgen, Inc. Announces Participation at XSITE 2009
Jun 9, 2009
Summary ToggleAmerican Diabetes Association Awards Leaders in the Field

Researchers, clinicians and educators acknowledged for their accomplishments in diabetes

Summary ToggleAmerican Diabetes Association Awards Leaders in the Field
Jun 8, 2009
Summary ToggleGroundbreaking Approach to Treating Obesity Highlighted by Keynote Lecture at American Diabetes Association Annual Scientific Sessions

Zafgen Scientific Advisory Board Member and Pioneering Researcher Dr. Randy J. Seeley Underscores the Active Role of Adipose Vasculature in Metabolic Disease

Summary ToggleGroundbreaking Approach to Treating Obesity Highlighted by Keynote Lecture at American Diabetes Association Annual Scientific Sessions
May 14, 2009
Summary ToggleZafgen, Inc. Announces Participation at BIO 2009 International Convention Summary ToggleZafgen, Inc. Announces Participation at BIO 2009 International Convention
May 5, 2009
Summary ToggleZafgen, Inc. Appoints Matthias Jaffe to Chief Financial Officer and Vice President of Business Development

Industry Executive Brings Extensive Experience to Novel Obesity Therapeutics Company

Summary ToggleZafgen, Inc. Appoints Matthias Jaffe to Chief Financial Officer and Vice President of Business Development
Apr 27, 2009
Summary ToggleZafgen, Inc. to Present at Xconomy Forum Summary ToggleZafgen, Inc. to Present at Xconomy Forum